Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.51
SNY's Cash to Debt is ranked higher than
56% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.07 vs. SNY: 0.51 )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: 10.62
Current: 0.51

0.14
10.62
Equity to Asset 0.58
SNY's Equity to Asset is ranked higher than
68% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. SNY: 0.58 )
SNY' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.65
Current: 0.58

0.48
0.65
Interest Coverage 10.15
SNY's Interest Coverage is ranked higher than
54% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 236.52 vs. SNY: 10.15 )
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 10.15

7.88
19.65
F-Score: 7
Z-Score: 2.58
M-Score: -2.74
WACC vs ROIC
7.84%
12.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.01
SNY's Operating margin (%) is ranked higher than
88% of the 1104 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.08 vs. SNY: 18.01 )
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 18.01

15.25
38.21
Net-margin (%) 12.87
SNY's Net-margin (%) is ranked higher than
86% of the 1104 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.42 vs. SNY: 12.87 )
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.87

7.92
25.8
ROE (%) 13.33
SNY's ROE (%) is ranked higher than
83% of the 1133 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. SNY: 13.33 )
SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 13.33

5.18
33.55
ROA (%) 7.72
SNY's ROA (%) is ranked higher than
82% of the 1166 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. SNY: 7.72 )
SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 7.72

2.62
21.59
ROC (Joel Greenblatt) (%) 64.81
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. SNY: 64.81 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.22   Max: 145.55
Current: 64.81

31.22
145.55
Revenue Growth (3Y)(%) -1.00
SNY's Revenue Growth (3Y)(%) is ranked higher than
61% of the 941 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNY: -1.00 )
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1   Max: 27.4
Current: -1

-1
27.4
EBITDA Growth (3Y)(%) -4.40
SNY's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 840 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SNY: -4.40 )
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4   Max: 35.7
Current: -4.4

-4.4
35.7
EPS Growth (3Y)(%) -8.20
SNY's EPS Growth (3Y)(%) is ranked higher than
65% of the 818 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. SNY: -8.20 )
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.8   Max: 41.2
Current: -8.2

-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.30%)
Ken Fisher 13,079,575 sh (+1.18%)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
Jean-Marie Eveillard 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
Jean-Marie Eveillard 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

Steven Cohen 1,050,000 sh (New)
David Dreman 1,102 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Jean-Marie Eveillard 34,157 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
Q1 2015

SNY Guru Trades in Q1 2015

Francis Chou 410,000 sh (unchged)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
sing the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were held by the highest number of gurus. Read more...
Oakmark Funds' Bill Nygren Buys 4 New Stocks
Bill Nygren (Trades, Portfolio)’s Oakmark fund beat the S&P 500 for the first quarter with a 5% gain compared to the index’s 2% rise. In his first quarter letter, he attributed the strong quarter primarily to Forest Laboratories being acquired by Actavis Plc (ACT), and large exposure to auto-related cyclical and financials. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.00
SNY's P/E(ttm) is ranked higher than
82% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 63.00 vs. SNY: 29.00 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 38.97
Current: 29

9.64
38.97
Forward P/E 8.32
SNY's Forward P/E is ranked higher than
98% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 8.32 )
N/A
PE(NRI) 29.20
SNY's PE(NRI) is ranked higher than
84% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 60.60 vs. SNY: 29.20 )
SNY' s 10-Year PE(NRI) Range
Min: 9.82   Max: 39.2
Current: 29.2

9.82
39.2
P/B 2.20
SNY's P/B is ranked higher than
79% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. SNY: 2.20 )
SNY' s 10-Year P/B Range
Min: 1.11   Max: 5.88
Current: 2.2

1.11
5.88
P/S 3.71
SNY's P/S is ranked higher than
63% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. SNY: 3.71 )
SNY' s 10-Year P/S Range
Min: 1.77   Max: 5.18
Current: 3.71

1.77
5.18
PFCF 16.30
SNY's PFCF is ranked higher than
93% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 16.30 )
SNY' s 10-Year PFCF Range
Min: 5.11   Max: 45
Current: 16.3

5.11
45
POCF 12.82
SNY's POCF is ranked higher than
92% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.09 vs. SNY: 12.82 )
SNY' s 10-Year POCF Range
Min: 4.15   Max: 23.37
Current: 12.82

4.15
23.37
EV-to-EBIT 22.46
SNY's EV-to-EBIT is ranked higher than
83% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.34 vs. SNY: 22.46 )
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5   Max: 204.2
Current: 22.46

10.5
204.2
Shiller P/E 24.40
SNY's Shiller P/E is ranked higher than
90% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 24.40 )
SNY' s 10-Year Shiller P/E Range
Min: 11.39   Max: 25.45
Current: 24.4

11.39
25.45
Current Ratio 1.80
SNY's Current Ratio is ranked higher than
64% of the 1025 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.23 vs. SNY: 1.80 )
SNY' s 10-Year Current Ratio Range
Min: 0.79   Max: 2.71
Current: 1.8

0.79
2.71
Quick Ratio 1.29
SNY's Quick Ratio is ranked higher than
63% of the 1025 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. SNY: 1.29 )
SNY' s 10-Year Quick Ratio Range
Min: 0.59   Max: 2.41
Current: 1.29

0.59
2.41
Days Inventory 191.96
SNY's Days Inventory is ranked higher than
62% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 141.94 vs. SNY: 191.96 )
SNY' s 10-Year Days Inventory Range
Min: 155.87   Max: 224.59
Current: 191.96

155.87
224.59
Days Sales Outstanding 76.50
SNY's Days Sales Outstanding is ranked higher than
75% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.70 vs. SNY: 76.50 )
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29   Max: 103.32
Current: 76.5

61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.72
SNY's Dividend Yield is ranked higher than
93% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. SNY: 3.72 )
SNY' s 10-Year Dividend Yield Range
Min: 1.41   Max: 5.46
Current: 3.72

1.41
5.46
Dividend Payout 0.84
SNY's Dividend Payout is ranked higher than
72% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 0.84 )
SNY' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1
Current: 0.84

0.27
1
Dividend growth (3y) 3.80
SNY's Dividend growth (3y) is ranked higher than
72% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. SNY: 3.80 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 29.6
Current: 3.8

0
29.6
Yield on cost (5-Year) 4.72
SNY's Yield on cost (5-Year) is ranked higher than
90% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. SNY: 4.72 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8   Max: 6.97
Current: 4.72

1.8
6.97
Share Buyback Rate -0.10
SNY's Share Buyback Rate is ranked higher than
84% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. SNY: -0.10 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 53.00
SNY's Price/Tangible Book is ranked lower than
61% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. SNY: 53.00 )
SNY' s 10-Year Price/Tangible Book Range
Min: 6.59   Max: 2093.5
Current: 53

6.59
2093.5
Price/DCF (Projected) 1.00
SNY's Price/DCF (Projected) is ranked higher than
97% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 1.00 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 1.02
Current: 1

0.48
1.02
Price/Median PS Value 1.30
SNY's Price/Median PS Value is ranked higher than
74% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. SNY: 1.30 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.65
Current: 1.3

0.69
2.65
Price/Graham Number 8.10
SNY's Price/Graham Number is ranked higher than
68% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 8.10 )
SNY' s 10-Year Price/Graham Number Range
Min: 1.94   Max: 6.42
Current: 8.1

1.94
6.42
Earnings Yield (Greenblatt) 4.50
SNY's Earnings Yield (Greenblatt) is ranked higher than
79% of the 1150 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. SNY: 4.50 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.5
Current: 4.5

0.5
9.5
Forward Rate of Return (Yacktman) 1.97
SNY's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. SNY: 1.97 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 59.3
Current: 1.97

1.7
59.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SANNV.France, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Mt Stocks Apr 19 2015 
Scottrade Mar 22 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 
Dodge & Cox's Stock Fund Q4 2014 Commentary Jan 20 2015 


More From Other Websites
Bristol's Opdivo Scores Again Against Lung Cancer Apr 17 2015
Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog Apr 16 2015
The Medicines Co.'s Kengreal Briefing Documents Positive - Analyst Blog Apr 14 2015
Fewer CEOs Fired and More Retired Save Shareholders Billions Apr 13 2015
Fewer CEOs Are Being Fired and That's Good News for Shareholders Apr 13 2015
Wave of interest in gene therapy brings Voyager a new $60M investment Apr 13 2015
Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at... Apr 13 2015
Trade Europe and a Strong USD with this ETF Apr 10 2015
Inverse Head and Shoulders Patterns Breaking Out Apr 09 2015
What Really Happens To Stocks When The Fed Tightens Monetary Policy? Apr 08 2015
FDA accepts Novo Nordisk's resubmitted application for insulin drug Apr 07 2015
Sanofi: Shantha will provide up to 37 million doses of Shan5(TM) Apr 07 2015
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM)... Apr 07 2015
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) Apr 07 2015
[$$] Bristol-Myers Invests in Dutch Company uniQure Apr 06 2015
Alnylam to move HQ to former Vertex site in big 2018 biotech shuffle Apr 06 2015
GlaxoSmithKline to move 150 Cambridge vaccine research jobs out of state Apr 03 2015
Foreign-owned companies find Mass. appeal-ing Apr 03 2015
Boston Business Journal announces 2015 Women to Watch in Science and Technology honorees Apr 02 2015
BioMed scores against rival Alexandria with new lease to Biogen Apr 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK